pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$OMEROMEROS CORP

$OMER18.63+1.31%
Seattle, WA, USupdated 5h ago

Omeros is an epic poem by Saint Lucian writer Derek Walcott, first published in 1990. The work is divided into seven "books" containing a total of sixty-four chapters. Many critics view Omeros as Walcott's finest work.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval2 co-mentions · 1 sources
  • drugYARTEMLEA2 co-mentions · 1 sources
  • drugnarsoplimab2 co-mentions · 1 sources
pipeline
3
marketed
1
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Phase 1: 1Marketed: 1Unknown: 1
1Phase 11Marketed1Unknown
Marketed
narsoplimab
Coronavirus Disease 2019 (COVID-19)
Phase 1
OMS-527
Substance (Drug) Abuse
drug
YARTEMLEA
1 INDICATIONS AND USAGE YARTEMLEA is indicated for the tr…

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Aug 13, 2026
earnings
$OMER18.63+1.31%
8d ago
OMEROS CORP earnings
OMEROS CORP
→
view all catalysts →

Active trials

  • phase1Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuriacompletedn=15
  • phase2Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721terminatedn=31
  • —Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimabapproved for marketing
  • phase3Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrometerminatedn=6
  • phase3Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathyterminatedn=360
  • phase2Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumabcompletedn=12
  • phase2Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNrecruitingn=20
  • phase2Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMArecruitingn=18
more trials →
🐶 Hiring Signal
No open roles indexed yet — view OMEROS CORP jobs →

News

no news has mentioned this company yet
identifiers
ticker
$OMER
SEC CIK
0001285819
country
US
source
sec_tickers
top tags
Cardiology1Infectious Disease1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 29m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?